Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1633-1642

  Gertz, Michael ^a   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BUSPIRONE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; FELODIPINE; INDINAVIR; MEVINOLIN; MIDAZOLAM; NISOLDIPINE; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TERFENADINE;

ACCURACY; ADULT; AGED; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; ENZYME SUBSTRATE; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; MICROSOME; NONHUMAN; OBSERVATIONAL STUDY; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; SMALL INTESTINE ABSORPTION; STATISTICAL MODEL;

ADULT; AGED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINES; LIVER; MALE; MICROSOMES; MIDDLE AGED; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACOKINETICS; YOUNG ADULT;

EID: 80052002510     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039248     Document Type: Article

References (49)

1. Agoram B., Woltosz WS, and Bolger M.B. (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 (Suppl 1):S41-S67. (Pubitemid 32905355)
2. Berggren S., Gall C., Wollnitz N., Ekelund M., Karlbom U., Hoogstraate J., Schrenk D, and Lennernäs H. (2007) Gene and protein expression of P- Glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 4:252-257. (Pubitemid 46640601)
3. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg LR, and Beliles R.P. (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484. (Pubitemid 27314117)
4. Chalasani N., Gorski J.C., Patel N.H., Hall SD, and Galinsky R.E. (2002) Reply to Rostami- Hodjegan and Tucker 2002; Hepatology 35(5): 1549- Hodjegan and Tucker 2002; Hepatology 35(5): 15491550. Hepatology 35:1550-1551.
5. Clifford C.P., Adams D.A., Murray S., Taylor G.W., Wilkins M.R., Boobis AR, and Davies D.S. (1997) The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52:311-315. (Pubitemid 27283300)
6. Darwich A.S., Neuhoff S., Jamei M, and Rostami-Hodjegan A. (2011) Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 11:716-729.
7. Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts JP, and Hebert M.F. (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49. (Pubitemid 27327098)
8. Galetin A., Gertz M, and Houston J.B. (2008) Potential role of intestinal first- Pass metabolism in the prediction of drug- Pass metabolism in the prediction of drugDrug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
9. Gammans R.E., Mayol RF, and LaBudde J.A. (1986) Metabolism and disposition of buspirone. Am J Med 80 (3B):41-51. (Pubitemid 16097584)
10. Gertz M., Davis J.D., Harrison A., Houston JB, and Galetin A. (2008a) Grapefruit juice- Drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9:785-795.
11. Gertz M., Harrison A., Houston JB, and Galetin A. (2010) Prediction of human intestinal first- Pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
12. Gertz M., Kilford P.J., Houston JB, and Galetin A. (2008b) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
13. Granger D.N., Richardson P.D., Kvietys PR, and Mortillaro N.A. (1980) Intestinal blood flow. Gastroenterology 78:837-863. (Pubitemid 10111952)
14. Hebert M.F., Fisher R.M., Marsh C.L., Dressler D, and Bekersky I. (1999) Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96. (Pubitemid 29053157)
15. Hintz RJ and Johnson K.C. (1989) The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 51:9-17. (Pubitemid 19087827)
16. International Commission on Radiological Protection (2002) ICRP Publication 89: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values (Valetin J ed), Pergamon, Oxford, UK.
17. Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., Benet LZ, and Christians U. (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3- Hydroxy3Methylglutaryl- Hydroxy3MethylglutarylCoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369-1378.
18. Jajoo H.K., Mayol R.F., LaBudde JA, and Blair I.A. (1989) Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 17:634-640. (Pubitemid 20015104)
19. Jamei M., Turner D., Yang J., Neuhoff S., Polak S., Rostami-Hodjegan A, and Tucker G. (2009) Population- Based mechanistic prediction of oral drug absorption. AAPS J 11:225-237.
20. Kameyama Y., Yamashita K., Kobayashi K., Hosokawa M, and Chiba K. (2005) Functional characterization of SLCO1B1 (OATP- C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
21. Kolars J.C., Lown K.S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S.A., Merion RM, and Watkins P.B. (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259. (Pubitemid 24337433)
22. Lampen A., Christians U., Bader A., Hackbarth I, and Sewing K.F. (1996) Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52:159-168. (Pubitemid 26076283)
23. Lampen A., Christians U., Guengerich F.P., Watkins P.B., Kolars J.C., Bader A., Gonschior A.K., Dralle H., Hackbarth I, and Sewing K.F. (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-1324. (Pubitemid 26007838)
24. Lennernäs H. (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
25. Mouly S and Paine M.F. (2003) P- Glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599. (Pubitemid 37268274)
26. Nakamura T., Sakaeda T., Ohmoto N., Tamura T., Aoyama N., Shirakawa T., Kamigaki T., Nakamura T., Kim K.I., Kim S.R., et al. (2002) Real- Time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A- Time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3AMRNA levels in Caco- Time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3AMRNA levels in Caco2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas Drug Metab Dispos 30:4-6.
27. Nestorov I. (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
28. Obach RS and Reed-Hagen A.E. (2002) Measurement of Michaelis constants for cytochrome P450- Mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837. (Pubitemid 34671096)
29. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie AE, and Zeldin D.C. (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
30. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins JD, and Thummel K.E. (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A- Dependent metabolism. J Pharmacol Exp Ther 283:1552-1562. (Pubitemid 28016533)
31. Pasanen M.K., Fredrikson H., Neuvonen PJ, and Niemi M. (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733. (Pubitemid 350114817)
32. Poulin P and Theil F.P. (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism- Based prediction of volume of distribution. J Pharm Sci 91:129-156. (Pubitemid 34074473)
33. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson PG, and Baillie T.A. (2002) Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512. (Pubitemid 34456970)
34. Rodgers T., Leahy D, and Rowland M. (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to- ToStrong bases. J Pharm Sci 94:1259-1276. (Pubitemid 40904190)
35. Rodgers T and Rowland M. (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257. (Pubitemid 43874439)
36. Rostami-Hodjegan A and Tucker G.T. (2002) The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 35:1549-1550; author reply 1550-1551.
37. Rostami-Hodjegan A and Tucker G.T. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
38. Shen D.D., Kunze KL, and Thummel K.E. (1997) Enzyme- Catalyzed processes of first- Catalyzed processes of firstPass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127. (Pubitemid 27417869)
39. Strassburg C.P., Barut A., Obermayer-Straub P., Li Q., Nguyen N., Tukey RH, and Manns M.P. (2001) Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP- Glucuronosyltransferase: UGT2B7. J Hepatol 34:865-872. (Pubitemid 32595186)
40. Tam D., Tirona RG, and Pang K.S. (2003) Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31:373-383. (Pubitemid 36378514)
41. Thörn M., Finnström N., Lundgren S., Rane A, and Lööf L. (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54-60.
42. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins JD, and Wilkinson G.R. (1996) Oral first- Pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A- Pass elimination of midazolam involves both gastrointestinal and hepatic CYP3AMediated metabolism. Clin Pharmacol Ther 59:491-502. (Pubitemid 26193889)
43. Von Richter O., Burk O., Fromm M.F., Thon K.P., Eichelbaum M, and Kivistö K.T. (2004) Cytochrome P450 3A4 and P- Glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172-183. (Pubitemid 38314866)
44. Yang J., Jamei M., Yeo K.R., Tucker GT, and Rostami-Hodjegan A. (2007) Prediction of intestinal first- Pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
45. Yeh K.C., Stone J.A., Carides A.D., Rolan P., Woolf E, and Ju W.D. (1999) Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model- Independent data analysis. J Pharm Sci 88:568-573. (Pubitemid 29220986)
46. Yu LX and Amidon G.L. (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125. (Pubitemid 29459038)
47. Yu L.X., Lipka E., Crison JR, and Amidon G.L. (1996) Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 19:359-376. (Pubitemid 26227526)
48. Zhang Q.Y., Dunbar D., Ostrowska A., Zeisloft S., Yang J, and Kaminsky L.S. (1999) Characterization of human small intestinal cytochromes P- 450. Drug Metab Dispos 27:804-809. (Pubitemid 29297778)
49. Zhu M., Zhao W., Jimenez H., Zhang D., Yeola S., Dai R., Vachharajani N, and Mitroka J. (2005) Cytochrome P450 3A- Mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33:500-507. (Pubitemid 40393192)